424 related articles for article (PubMed ID: 27167195)
1. Management of hepatocellular carcinoma: an overview of major findings from meta-analyses.
Qi X; Zhao Y; Li H; Guo X; Han G
Oncotarget; 2016 Jun; 7(23):34703-51. PubMed ID: 27167195
[TBL] [Abstract][Full Text] [Related]
2. Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation.
Peng Z; Chen S; Wei M; Lin M; Jiang C; Mei J; Li B; Wang Y; Li J; Xie X; Chen M; Qian G; Kuang M
Radiology; 2018 May; 287(2):705-714. PubMed ID: 29390197
[TBL] [Abstract][Full Text] [Related]
3. Liver tumors and loco-regional therapy.
Vogel W
Wien Med Wochenschr; 2013 Mar; 163(5-6):107-8. PubMed ID: 23456251
[No Abstract] [Full Text] [Related]
4. Multimodality therapy and liver transplantation for hepatocellular carcinoma: a 14-year prospective analysis of outcomes.
Ramanathan R; Sharma A; Lee DD; Behnke M; Bornstein K; Stravitz RT; Sydnor M; Fulcher A; Cotterell A; Posner MP; Fisher RA
Transplantation; 2014 Jul; 98(1):100-6. PubMed ID: 24503764
[TBL] [Abstract][Full Text] [Related]
5. Clinical value of continuous administration of sorafenib in combination with modified transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.
Huang YH; Chen W; Li JP; Chen B; Yang JY
Chin Med J (Engl); 2013 Jan; 126(2):385-6. PubMed ID: 23324295
[No Abstract] [Full Text] [Related]
6. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
[TBL] [Abstract][Full Text] [Related]
7. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Li L; Zhao W; Wang M; Hu J; Wang E; Zhao Y; Liu L
BMC Gastroenterol; 2018 Sep; 18(1):138. PubMed ID: 30180810
[TBL] [Abstract][Full Text] [Related]
8. Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma.
Eggert T; Greten TF
Digestion; 2017; 96(1):1-4. PubMed ID: 28605745
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM.
Bouattour M; Soubrane O; de Gramont A; Faivre S
Trials; 2016 Nov; 17(1):563. PubMed ID: 27887632
[TBL] [Abstract][Full Text] [Related]
10. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
Vilgrain V; Abdel-Rehim M; Sibert A; Ronot M; Lebtahi R; Castéra L; Chatellier G;
Trials; 2014 Dec; 15():474. PubMed ID: 25472660
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Transarterial Chemoembolization Combined with Radiofrequency Ablation Therapy
Yi PS; Huang M; Zhang M; Xu L; Xu MQ
Am Surg; 2018 Feb; 84(2):282-288. PubMed ID: 29580359
[TBL] [Abstract][Full Text] [Related]
12. Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review.
de'Angelis N; Landi F; Carra MC; Azoulay D
World J Gastroenterol; 2015 Oct; 21(39):11185-98. PubMed ID: 26494973
[TBL] [Abstract][Full Text] [Related]
13. Current management of hepatocellular carcinoma.
Mendizabal M; Reddy KR
Med Clin North Am; 2009 Jul; 93(4):885-900, viii. PubMed ID: 19577120
[TBL] [Abstract][Full Text] [Related]
14. Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?
Sacco R; Antonucci M; Bargellini I; Marceglia S; Mismas V; Cabibbo G
Future Oncol; 2015; 11(17):2371-3. PubMed ID: 26270206
[No Abstract] [Full Text] [Related]
15. Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Geschwind JF; Chapiro J
Clin Adv Hematol Oncol; 2016 Aug; 14(8):585-7. PubMed ID: 27487101
[No Abstract] [Full Text] [Related]
16. JAMA PATIENT PAGE. Treatment of Liver Cancer.
Mokdad AA; Singal AG; Yopp AC
JAMA; 2016 Jan; 315(1):100. PubMed ID: 26746473
[No Abstract] [Full Text] [Related]
17. Liver resection for hepatocellular carcinoma in patients with hematological malignancies.
Lin HC; Yang YS; Teng CJ; Shen CH; Jan YG; Cheng SB; Wu CC; Lin YL; Huang CC; P'eng FK
World J Surg Oncol; 2017 Nov; 15(1):194. PubMed ID: 29096656
[TBL] [Abstract][Full Text] [Related]
18. Management of hepatocellular carcinoma with portal vein thrombosis.
Quirk M; Kim YH; Saab S; Lee EW
World J Gastroenterol; 2015 Mar; 21(12):3462-71. PubMed ID: 25834310
[TBL] [Abstract][Full Text] [Related]
19. Practical Considerations of Real Life of Hepatocellular Carcinoma in a Tertiary Center of Brazil.
Almeida-Carvalho SR; Gomes-Ferraz ML; Loureiro-Matos CA; Benedito-Silva AT; Carvalho-Filho RJ; Renato-Perez R; Miziara-Gonzalez A; Salzedas-Netto AA; Szejnfeld D; D'Ippolito G; Pereira-Lanzoni V; Souza-Silva I
Ann Hepatol; 2017; 16(2):255-262. PubMed ID: 28233747
[TBL] [Abstract][Full Text] [Related]
20. Recurrent hepatocellular carcinoma in liver transplant recipients: parameters affecting time to recurrence, treatment options and survival in the sorafenib era.
Pfiffer TE; Seehofer D; Nicolaou A; Neuhaus R; Riess H; Trappe RU
Tumori; 2011; 97(4):436-41. PubMed ID: 21989430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
